Healthcare · Biotechnology
Price
$3.92
Market Cap
$2.3M
Employees
4
Beta
1.03
Avg Volume
1,459,127
CEO
Rami Levin
Business Description
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.11
Stock Price: $3.92
EPS (Diluted): -35.75
EPS (Diluted): -35.75
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.51
Stock Price: $3.92
Total Equity: $4.52M
Shares: 443,369
Total Equity: $4.52M
Shares: 443,369
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.29
Market Cap: $2.25M
Total Debt: $328,571
Cash: $7.20M
EBITDA: -$15.83M
Total Debt: $328,571
Cash: $7.20M
EBITDA: -$15.83M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$4.5M
Market Cap: $2.25M
Total Debt: $328,571
Cash: $7.20M
Total Debt: $328,571
Cash: $7.20M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $3.92
Revenue: $0.00
Shares: 443,369
Revenue: $0.00
Shares: 443,369
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$15.99M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$15.85M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-350.5%
Net Income: -$15.85M
Total Equity: $4.52M
Total Equity: $4.52M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
680.3%
Operating Income: -$15.99M
Tax Rate: 0.0%
Equity: $4.52M
Total Debt: $328,571
Cash: $7.20M
Tax Rate: 0.0%
Equity: $4.52M
Total Debt: $328,571
Cash: $7.20M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.98
Current Assets: $8.10M
Current Liabilities: $4.10M
Current Liabilities: $4.10M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.07
Short-Term Debt: $328,571
Long-Term Debt: $0.00
Total Debt: $328,571
Total Equity: $4.52M
Long-Term Debt: $0.00
Total Debt: $328,571
Total Equity: $4.52M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 443,369
Shares: 443,369
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$10.20
Total Equity: $4.52M
Shares: 443,369
Shares: 443,369
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-31.19
Operating CF: -$13.81M
CapEx: -$18,175
Shares: 443,369
CapEx: -$18,175
Shares: 443,369
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.92
Stock Price: $3.92
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$15.85M
Net Income: -$15.85M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CNSP against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 4:25pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $13,070 | $11,756 | $4,134 | $3,306 | $0 |
| Gross Profit | $-13,070 | $-11,756 | $-4,134 | $-3,306 | $0 |
| Operating Expenses | $14.5M | $14.9M | $18.9M | $14.9M | $16.0M |
| Operating Income | -$14.5M | -$14.9M | -$18.9M | -$14.9M | -$16.0M |
| Net Income | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| EBITDA | -$14.5M | -$15.3M | -$18.8M | -$14.8M | -$15.8M |
| EPS | $-495,027.00 | $-336,499.00 | $-150,114.00 | $-466.44 | $-35.75 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 4:25pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5.0M | $10.1M | $548,721 | $6.5M | $7.2M |
| Total Current Assets | $7.5M | $12.6M | $1.6M | $8.7M | $8.1M |
| Total Assets | $8.8M | $13.1M | $1.7M | $8.7M | $8.6M |
| Current Liabilities | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.1M | $4.9M | $6.1M | $2.5M | $4.1M |
| Total Equity | $6.6M | $8.1M | -$4.4M | $6.2M | $4.5M |
| Retained Earnings | -$35.0M | -$50.7M | -$69.6M | -$84.4M | -$100.3M |
Cash Flow (Annual)
Last updated: Jun 22, 2026 4:25pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Capital Expenditure | $-5,748 | $-4,422 | $-3,901 | $-4,188 | $-18,175 |
| Free Cash Flow | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $-2,043 |
| Net Change in Cash | -$9.0M | $5.1M | -$9.5M | $5.9M | $739,636 |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:10am (21h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$50.0M $50.0M – $50.0M
|
$76.2M $76.2M – $76.2M
|
$0 |
$77.3M $77.3M – $77.3M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
$-735,994 $-735,994 – $-735,994
|
$-833,535 $-833,535 – $-833,535
|
$-882,306 $-882,306 – $-882,306
|
$1.0M $1.0M – $1.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 4:25pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | +10.1% | +64.8% | +20.0% | +100.0% |
| Operating Income Growth | -3.1% | -26.3% | +21.0% | -7.3% |
| Net Income Growth | -5.4% | -23.4% | +21.2% | -6.7% |
| EBITDA Growth | -5.4% | -23.5% | +21.2% | -6.7% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CNSP — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CNSP.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30